Imunon (IMNN) investor relations material

Executive summary

• OVATION three Phase III trial for IMNN-001 in advanced ovarian cancer is progressing ahead of schedule, with strong early enrollment and investigator enthusiasm, supported by positive Phase 2 results showing improved survival and safety.

• Recent R&D day and presentations at major oncology conferences highlighted IMNN-001's transformative potential, robust mechanistic data, and significant unmet needs in ovarian cancer.

• IMNN-001 demonstrated a clinically meaningful 13-month median overall survival benefit in Phase 2, with robust immune activation and favorable safety profile.

• PlaCCine DNA vaccine platform completed Phase 1 trial for COVID-19 booster, demonstrating safety, durable immunogenicity, and ongoing efforts to secure strategic partnerships.

Financial highlights

• Cash and cash equivalents stood at $5.3 million as of September 30, 2025.

• Net loss for Q3 2025 was $3.4 million ($1.16/share), improved from $4.8 million ($3.76/share) in Q3 2024; nine-month net loss was $10.3 million ($5.53/share), down from $14.6 million ($14.13/share) year-over-year.

• R&D expenses for Q3 2025 were $1.9 million, down from $3.3 million year-over-year; G&A expenses were $1.6 million, down from $1.7 million.

• $4.5 million raised in Q3 2025 through warrant exercises and ATM facility.

• Operating expenses for the nine months ended September 30, 2025, were 31% lower year-over-year.

Outlook and guidance

• Cash runway extends into mid-Q1 2026, with plans to further extend through non-dilutive transactions, partnerships, and additional capital raises.

• Full enrollment in OVATION three expected by late 2028, with potential acceleration if additional financing is secured.

• No revenue expected from product sales in the next several years; continued operating losses anticipated.

• Multiple near-term catalysts include enrollment momentum, scientific presentations, and partnership progress.